- Terumo Corporation has completed the acquisition of a Drug Product Plant and Quality Control Laboratory from WuXi Biologics in Leverkusen, Germany, officially closing on September 30, 2025.
- The acquisition expands Terumo’s CDMO and contract manufacturing capabilities, offering fill & finish services for vials and prefillable syringes, including device assembly.
Terumo Corporation has finalised the acquisition of a Drug Product Plant and associated Quality Control Laboratory from WuXi Biologics in Leverkusen, Germany, with the transaction officially closing on 30 September 2025. The move strengthens Terumo’s position in the CDMO sector and broadens its integrated service offerings for biopharmaceutical companies.
The newly acquired Leverkusen facility operates under current Good Manufacturing Practice (cGMP) standards and is staffed by experienced professionals. Terumo plans to leverage the site to provide fill & finish services for vials and polymer prefillable syringes, as well as device assembly, to meet growing demand in Europe and the United States.
“Our expanded footprint in Europe and unique CDMO capabilities will empower biopharmaceutical companies to bring effective treatments for chronic diseases to market more efficiently.”
Noritsugu Fujita, Division President of Terumo’s Pharmaceutical Solutions Division
Terumo currently operates three CDMO production facilities in Japan, located in Kofu, Fujinomiya, and Yamaguchi. The company has recently expanded production lines at Yamaguchi and is installing new lines in Kofu, scheduled for completion by the end of 2025. The addition of the Leverkusen plant establishes a strategic European base to better support global pharmaceutical clients.
“With our integrated solution – from primary container and fill & finish capabilities to device assembly – customers can bring us their Active Pharmaceutical Ingredient (API) and leave with fully assembled auto-injectors. This is a win-win for both patients and healthcare system, as self-injection systems offer a more cost-effective and patient-friendly way to administer injectable drugs.”
Marco Chiadò Piat, President of Pharmaceutical Solutions at Terumo
Terumo’s expertise includes the development of pharmaceutical primary containers such as prefillable syringes, drug delivery devices, and combination products integrating pharmaceuticals and medical devices. Expanding its global CDMO operations remains a central part of the company’s growth strategy.
